Functional peptides by genome reverse engineering

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 3, 2007, Pages 341-346

  Grigorov, Martin G ^a   Van Bladeren, Peter J ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Bioactive peptides; Bioinformatics; Chemoinformatics; Crypteins; Design of bioactive molecules; In silico screening; Structure based drug design

Indexed keywords

ALPHA INTERMEDIN; BETA ENDORPHIN; BETA INTERMEDIN; BETA LIPOTROPIN; CORTICOTROPIN[18-39]; GAMMA INTERMEDIN; MONOCLONAL ANTIBODY; N TERMINAL PROPIOMELANOCORTIN; NEW DRUG; PEPTIDE; PRODYNORPHIN; PROENKEPHALIN; PROPIOMELANOCORTIN; PROPIOMELANOCORTIN JOINING PEPTIDE; PROSOMATOSTATIN; PROTEIN PRECURSOR; PROTHYROTROPIN RELEASING HORMONE; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

BIOINFORMATICS; BIOLOGY; COMPUTER PROGRAM; DRUG MARKETING; DRUG SCREENING; GASTROINTESTINAL TRACT; GENOME; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; LABORATORY; MOLECULAR BIOLOGY; PEPTIDE SYNTHESIS; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEOMICS; REVIEW; TRANSGENE;

COMPUTATIONAL BIOLOGY; DIFFUSION OF INNOVATION; DRUG DESIGN; GENE REGULATORY NETWORKS; GENOMICS; HUMANS; PEPTIDES; PROTEIN CONFORMATION; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 34249001936     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Terstappen GC, Reggiani A: In silico research in drug discovery. Trends Pharmacol Sci (2001) 22(1):23-26. •• A comprehensive review of the applications of computational biology and chemistry in the discovery of new bioactive molecules. The research demonstrates how this discovery is already moving toward electronic R&D.
2. Drews J: Drug discovery: A historical perspective. Science (2000) 287(5460):1960-1964.
3. Fischer E: [The influence of configuration on the activity of enzymes.] Ber Dtsch Chem Ges (1894) 27(3):2895-2993.
4. Ashton G: Growing pains for biopharmaceuticals. Nat Biotechnol (2001) 19(4):307-311. •• An important article reviewing the impact of biopharmaceuticals in the pharmaceutical industry.
5. Schmid EF, Smith DA: R&D technology investments: Misguided and expensive or a better way to discover medicines. Drug Disc Today (2006) 11(17/18):775-784.
6. Zhu H, Snyder M: 'Omic' approaches for unravelling signalling networks. Curr Opin Cell Biol (2002) 14(2):173-179.
7. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R et al: Initial sequencing and analysis of the human genome. Nature (2001) 409(6822):860-921.
8. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD et al: The sequence of the human genome. Science (2001) 291(5507):1304-1351.
9. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov (2002) 1(9):727-730.
10. Grigorov MG: Global properties of biological networks. Drug Disc Today (2005) 10(5):365-372.
11. Sharom JR, Bellows DS, Tyers M: From large networks to small molecules. Curr Opin Chem Biol (2004) 8(1):81-90. •• A review discussing how the cellular phenotypes observed at the macroscopic level depend on the collective characteristics of protein and genetic interaction networks. The authors propose how these networks can be modulated with rationally designed combinations of small molecules that are able to collectively shift network behaviour.
12. Albert R, Jeong H, Barabasi AL: Error and attack tolerance of complex networks. Nature (2000) 406(6794):378-382.
13. Morphy R, Kay C, Rankovic Z: From magic bullets to multiple ligands. Drug Disc Today (2004) 9(15):641-651.
14. Cavaletto M, Giuffrida MG, Conti A: The proteomic approach to human milk fat globule membrane. Clin Chim Acta (2004) 347 (1-2):41-48.
15. German BJ: Bioactive components in milk. Curr Opin Clin Nutr Metab Care (2002) 5(6):653-658.
16. Shoichet BK: Virtual screening of chemical libraries. Nature (2004) 432(7019):862-865.
17. Johnson MA, Maggiora GM: Introduction to similarity in chemistry. In: Concepts and Applications of Molecular Similarity. Johnson MA, Maggiora GM (Eds), John Wiley & Sons Ltd, New York, NY, USA (1990):1-13.
18. Klebe G: New leads out of the computer: Two alternative approaches. GIT Lab J Eur (2004) 8(2):56-57.
19. Agrafiotis DK, Lobanov VS, Salemme FR: Combinatorial informatics in the post-genomic era. Nat Rev Drug Discov (2002) 1(5):337-346.
20. Lyne PD: Structure-based virtual screening: An overview. Drug Disc Today (2002) 7(20):1047-1055.
21. Hardy LW, Malikayil A: The impact of structure-guided drug design on clinical agents. Curr Drug Disc (2003) 15(1):15-20. •• This important review reports on at least 50 examples where computational biology and chemistry contributed directly to the development and the launch of a new biopharmaceutical product.
22. Schuster D, Laggner C, Langer T: Why drugs fail - a study on side effects in new chemical entities. Curr Pharm Design (2005) 11(27):3545-3559. •• This important study focuses on the reasons for market withdrawals of drugs and drug development project terminations in phases I to III clinical trials from 1992 to 2002. It concludes that over 90% of the market withdrawals were caused by drug toxicity and that no major improvements of this attrition rate have been achieved in the last decade.
23. Lipinski CA, Lombardo F, Dominy BW, Feeny PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23(1-3):3-25.
24. Ajay A, Walters WP, Murcko MA: Can we learn to distinguish between "drug-like" and "nondrug-like" molecules. J Med Chem (1998) 41(18):3314-3324.
25. Sadowski J, Kubinyi H: A scoring scheme for discriminating between drugs and non-drugs. J Med Chem (1998) 41(18):3325-3329.
26. Wagener A, van Geerestein VJ: Potential drugs and nondrugs: Prediction and identification of important structural features. J Chem Inf Comput Sci (2000) 40(2):280-292.
27. Grigorov M: Computational molecular science for the life sciences industry. Chimia (2005) 59(7/8):550-553.
28. Altshuler J, Flanagan A, Guy P, Steiner M, Tollman P: A revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry. Boston Consulting Group Report (Andersen Consulting) (2001). http://www.bcg.com/publications/files/ eng_genomicsgenetics_rep_11_01.pdf •• This important marketing report reviews the economical parameters and performance of the research and development workflow within the biopharmaceutical industry and provides estimates of the impact of genomics and informatics on these parameters.
29. Alexander R, Spurlino J. Structural biology in early phase drug discovery. Front Drug Design Disc (2005) 1(1):287-296.
30. Verheij H, Robeson BL: The role of chemical diversity in drug discovery. Genome Proteome Technol (2002) 2(5):32-35.
31. Kingston DG, Newman DJ: Natural products as drug leads: An old process or the new hope for drug discovery? IDrugs (2005) 8(12):990-992.
32. Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod (2003) 66(7):1022-1037. •• In this important review the authors scrutinize a 22-year period from 1981 to 2002 to investigate the utility of natural products as sources of novel drug structures.
33. Walker MJA, Barrett T, Guppy LJ: Functional pharmacology: The drug discovery bottleneck? Drug Disc Today: Targets (2004) 3(5):208-215.
34. Walsh G: Biopharmaceutical benchmarks 2006. Nat Biotechnol (2006) 24(7):769-776.
35. Gosse ME, Manocchia M: The first biopharmaceuticals approved in the United States: 1980-1994. Drug Inf J (1996) 30(4):991-1001.
36. Van Brunt J: The payoff: Betting on protein drugs. Signals Magazine (June) (2000). http://www.signalsmag.com/signalsmag.nsf/ 657b06742b 5748e888256570005cba01/49437a968ee454e188256907000e7adc?Op enDocument
37. Marx V: Watching peptide drugs grow up. Chem Eng News (2005) 83(11):17-24.
38. Adermann K: Editorial. Curr Prot Pept Science (2005) 6(3):205-206.
39. McGee P: First successes turn tide for peptide therapeutics. Drug Disc Dev (2005) 4. http://www.dddmag.com/ShowPR_Print.aspx?PUB CODE=016&ACCT=1600000100&ISSUE=0504&RELTYPE=PR&PROD CODE=00000000&PRODLETT=X&CALLFROM=RELPGM
40. Loffet A: Peptides as drugs: Is there a market? In: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium. Lebl M, Houghten R (Eds), American Peptide Society, San Diego, USA (2001):214-217.
41. Parmar H: Strategic analysis of the therapeutic peptides market in Europe. Frost & Sullivan Report, Frost & Sullivan, London, UK (2004). •• An important review that discusses all of the parameters of peptides that contibute to them emerging as a new class of drugs, with a specific focus on the European market.
42. Hamman JH, Enslin GM, Kotze AF: Oral delivery of peptide drugs: Barriers and developments. BioDrugs (2005) 19(3):165-177.
43. Steiner DF: Peptide hormones, biosynthesis and posttranslational processing of. In: Encyclopedia of Endocrine Diseases. Martini L (Ed), Elsevier, Amsterdam, the Netherlands (2004) 3:545-555.
44. von Eggelkraut-Gottanka R, Beck-Sickinger AG: Biosynthesis of peptide hormones derived from precursor sequences. Curr Med Chem (2004) 11(20):2651-2665.
45. Autelitano DJ, Rajic A, Smith AI, Berndt MC, Ilag LL, Vadas M: The cryptome: A subset of the proteome, comprising cryptic peptides with distinct bioactivities. Drug Discov Today (2006) 11(7-8):306-314. •• This review discusses the new perspectives arising from the discovery that the proteolytic cleavage of proteins gives rise to 'hidden' peptides with bioactivities that are often unpredicted and totally distinct to the parent protein.
46. Ng JH, Ilag LL: Cryptic protein fragments as an emerging source of peptide drugs. IDrugs (2006) 9(5):343-346.
47. Ganapathy V, Gupta N, Martindale RG: Protein digestion and absorption. In: Physiology of Gastrointestinal Tract. Johnson LR, Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD (Eds), Elsevier, Amsterdam, the Netherlands (2006): 65.
48. Korhonen H, Pihlanto A: Bioactive peptides: Production and functionality. Int Dairy J (2006) 16(9):945-960.
49. Fitzgerald RJ, Murray BA: Bioactive peptides and lactic fermentations. Int J Dairy Techn (2006) 59(2):118-125.
50. Mizuno S, Nishimura S, Matsuura K, Gotou T, Yamamoto N: Release of short and proline-rich antihypertensive peptides from casein hydrolysate with an Aspergillus oryzae protease. J Dairy Sci (2004) 87(10):3183-3188.
51. Yamamoto N, Ejiri M, Mizuno S: Biogenic peptides and their potential use. Curr Pharm Des (2003) 9(16):1345-1355.
52. The Rice Genome. Science (2002) 296(5565).
53. Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD et al: The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Nat Acad Sci (2002) 99(22):14422-14427.
54. Barrett AJ: Bioinformatics of proteases in the MEROPS database. Curr Opin Drug Discovery Dev (2004) 7(3):334-341.
55. Loponen J: Angiotensin converting enzyme inhibitory peptides in Finnish cereals: A database survey. Agr Food Sci (2004) 13(1-2):39-45.
56. Edwards RJ, Moran N, Devocelle M, Kiernan A, Meade G, Signac W, Foy M, Park SD, Dunne E, Kenny D, Shields DC: Bioinformatic discovery of novel bioactive peptides. Nat Chem Biol (2007) 3(2):108-112.
57. Smith I: Cryptomics: Identification of novel bioactive peptides from intact proteins. Discovery Science and Biotechnology Meeting, Melbourne, Australia (2006).
58. CRYPTOME PHARMACEUTICALS LTD (Smith AI, Berndt M, Autelitano D, Csar X, Talbo GH): Method for detection of bioactive peptides. WO-2004008148 (2003).
59. MONSANTO COMPANY (Guan Z, Kellogg M, Tjoeng FS, Wang Q, Zhao JM, Mandrell K, Li W): Process for producing peptide sequences possessing anti-hypertension activity. WO-2001068115 (2001). •• This patent application is probably the first evidence for the industrial application of producing bioactive peptides by cleaving them from precursor protein raw materials using the relevant enzymes.
60. DSM IP ASSETS BV (Edens L, De Roos AL, Van Der Hoeven RAM, Deen PA): Blood pressure lowering protein hydrolysates. WO-2006005757 (2005).
61. NESTEC SA (Grigorov M, Van Bladeren P, Zachariae U Kochhar S, Fay LB, Corthesy I, Juillerat MA, Affolter M.): Bioactive compositions, natural methods of producing them and computational methods for designing natural production processes. US-2006210655 (2006).